Understanding the molecular heterogeneity of response and resistance to anti-HER2-ErbB2 agents in breast cancer

了解乳腺癌中抗 HER2-ErbB2 药物反应和耐药的分子异质性

• 批准号: nhmrc : 520365
• 负责人: A/Pr Sherene Loi
• 金额: $ 24.88万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/understanding-molecular-heterogeneity-breast-cancer/115786
• 关键词: Understanding; molecular; heterogeneity; response; resistance

A revolution in cancer care will take place in the next decade as we aim to individualize treatment for each patient. A subtype of breast cancer relies on a growth factor called HER2 for growth. Treatments that block HER2 are highly effective and have less side effects than chemotherapy. My study aims to further understand of the biology of this subtype of breast cancer and action of anti-HER2 agents as this will allow us to treat this aggressive type of breast cancer more effectively.

癌症护理的革命将在未来十年内进行，因为我们旨在为每个患者个性化治疗。乳腺癌的亚型依赖于称为HER2的生长因子的生长。与化学疗法相比，阻止HER2的治疗方法非常有效，副作用较小。我的研究旨在进一步了解这种乳腺癌亚型的生物学和抗HER2药物的作用，因为这将使我们能够更有效地治疗这种侵略性的乳腺癌。